When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?

被引：27

作者：

Smolen, Josef S. ^{[1
,2
]}

Weinblatt, Michael E. ^{[3
]}

机构：

[1] Med Univ Vienna, Dept Med 3, Div Rheumatol, A-1090 Vienna, Austria

[2] Hietzing Hosp, Vienna, Austria

[3] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2008年 / 67卷 / 11期

关键词：

D O I：

10.1136/ard.2008.098111

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1497 / 1498

页数：2

共 25 条

[1] The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses [J].

Aletaha, D ;

Smolen, JS .

RHEUMATOLOGY, 2002, 41 (12) :1367-1374

[2] Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety [J].

Alonso-Ruiz, Alberto ;

Pijoan, Jose Ignacio ;

Ansuategui, Eukene ;

Urkaregi, Arantxa ;

Calabozo, Marcelo ;

Quintana, Antonio .

BMC MUSCULOSKELETAL DISORDERS, 2008, 9 (1)

[3] Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles [J].

Anderson, PJ .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2005, 34 (05) :19-22

[4] Advances in targeted therapies X [J].

Breedveld, F. C. ;

Kalden, J. R. ;

Smolen, J. S. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 :1-1

[5] Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks [J].

Cohen, Stanley B. ;

Emery, Paul ;

Greenwald, Maria W. ;

Dougados, Maxime ;

Furie, Richard A. ;

Genovese, Mark C. ;

Keystone, Edward C. ;

Loveless, James E. ;

Burmester, Gerd-Ruediger ;

Cravets, Matthew W. ;

Hessey, Eva W. ;

Shaw, Timothy ;

Totoritis, Mark C. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2793-2806

[6] IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial [J].

Emery, P. ;

Keystone, E. ;

Tony, H. P. ;

Cantagrel, A. ;

van Vollenhoven, R. ;

Sanchez, A. ;

Alecock, E. ;

Lee, J. ;

Kremer, J. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) :1516-1523

[7] The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial [J].

Emery, P ;

Fleischmann, R ;

Filipowicz-Sosnowska, A ;

Schechtman, J ;

Szczepanski, L ;

Kavanaugh, A ;

Racewicz, AJ ;

Van Vollenhoven, RF ;

Li, NF ;

Agarwal, S ;

Hessey, EW ;

Shaw, TM .

ARTHRITIS AND RHEUMATISM, 2006, 54 (05) :1390-1400

[8] Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 [J].

Furst, D. E. ;

Breedveld, F. C. ;

Kalden, J. R. ;

Smolen, J. S. ;

Burmester, G. R. ;

Sieper, J. ;

Emery, P. ;

Keystone, E. C. ;

Schiff, M. H. ;

Mease, P. ;

van Riel, P. L. C. M. ;

Fleischmann, R. ;

Weisman, M. H. ;

Weinblatt, M. E. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 :2-22

[9] Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition [J].

Genovese, MC ;

Becker, J ;

Schiff, M ;

Luggen, M ;

Sherrer, Y ;

Kremer, J ;

Birbara, C ;

Box, J ;

Natarajan, K ;

Nuamah, I ;

Li, T ;

Aranda, R ;

Hagerty, DT ;

Dougados, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (11) :1114-1123

[10] Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period [J].

Gomez-Reino, JJ ;

Carmona, L .

ARTHRITIS RESEARCH & THERAPY, 2006, 8 (01)

← 1 2 3 →